X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will fund the Phase 2a clinical trial of the Company’s lead programme, ETD001, a novel first in class ENaC blocker, to deliver clinical proof of concept to treat cystic fibrosis.
Lead Product(s): ETD001
Therapeutic Area: Genetic Disease Product Name: ETD001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Panakes Partners
Deal Size: $33.1 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 30, 2024
Details:
By increasing the amount of airway fluid available to hydrate mucus, ETD001 addresses the underlying mechanisms of mucus congestion, and is expected to restore lung function, reduce the frequency of lung infections and improve patient quality of life.
Lead Product(s): ETD001
Therapeutic Area: Genetic Disease Product Name: ETD001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.
Lead Product(s): ETD002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETD002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $96.8 milion
Deal Type: Acquisition October 07, 2020
Details:
ETD002. The first-in-man safety study is being conducted in healthy participants with ETD002, a TMEM16A potentiator aimed at treating all people with cystic fibrosis (CF).
Lead Product(s): ETD002
Therapeutic Area: Genetic Disease Product Name: ETD002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance.
Lead Product(s): ETX001
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
